Journal
BIOMATERIALS SCIENCE
Volume 3, Issue 12, Pages 1519-1533Publisher
ROYAL SOC CHEMISTRY
DOI: 10.1039/c5bm00198f
Keywords
-
Categories
Funding
- National Institutes of Health (NIH) [R00CA160350, R01CA37393]
- Movember-PCF Challenge Award
- PCF Young Investigator Award
- DoD PCRP Postdoctoral Training Award [W81XWH-14-1-0268]
- NATIONAL CANCER INSTITUTE [R01CA037393, R00CA160350] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Messenger RNA (mRNA) has recently emerged with remarkable potential as an effective alternative to DNA-based therapies because of several unique advantages. mRNA does not require nuclear entry for transfection activity and has a negligible chance of integrating into the host genome which excludes the possibility of potentially detrimental genomic alternations. Chemical modification of mRNA has further enhanced its stability and decreased its activation of innate immune responses. Additionally, mRNA has been found to have rapid expression and predictable kinetics. Nevertheless, the ubiquitous application of mRNA remains challenging given its unfavorable attributes, such as large size, negative charge and susceptibility to enzymatic degradation. Further refinement of mRNA delivery modalities is therefore essential for its development as a therapeutic tool. This review provides an exclusive overview of current state-of-the-art biomaterials and nanotechnology platforms for mRNA delivery, and discusses future prospects to bring these exciting technologies into clinical practice.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available